TY - JOUR
T1 - PIAS3 suppresses NF-κB-mediated transcription by interacting with the p65/RelA subunit
AU - Jang, Hyun Duk
AU - Yoon, Kwiyeom
AU - Shin, Young Joo
AU - Kim, Jaesang
AU - Lee, Soo Young
PY - 2004/6/4
Y1 - 2004/6/4
N2 - Nuclear factor-κB (NF-κB) is a transcription factor critical for key cellular processes, including immune response, apoptosis, and cell cycle progression. A yeast two-hybrid screening, using the Rel homology domain (RHD) of the p65 subunit (RelA) of NF-κB as bait, led to the isolation of PIAS3, previously identified as a specific inhibitor of STAT3. We show that PIAS3 can directly associate with p65 using an in vitro pull-down and in vivo coimmunoprecipitation assays. When overexpressed, PIAS3 inhibits NF-κB-dependent transcription induced by treatment with tumor necrosis factor α (TNF-α) or interleukin-1β or by overexpression of TNF family receptors such as RANK, TNFR1, and CD30 or signal transducers of TNF receptor-associated factors (TRAFs), including TRAF2, TRAF5, and TRAF6. Down-regulation of PIAS3 by RNA interference reverses its effect on TNF-α-mediated NF-κB activation. We found that an N-terminal region of PIAS3 is necessary for both the interaction with p65 and the transcriptional suppression activity. In addition, we found that an LXXLL coregulator signature motif located within the N-terminal region of PIAS3 is the minimal requirement for the interaction with p65. Furthermore, we demonstrate that PIAS3 interferes with p65 binding to the CBP coactivator, thereby resulting in a decreased NF-κB-dependent transcription. Taken together, these data suggest that PIAS3 may function in vivo as a modulator in suppressing the transcriptional activity of p65.
AB - Nuclear factor-κB (NF-κB) is a transcription factor critical for key cellular processes, including immune response, apoptosis, and cell cycle progression. A yeast two-hybrid screening, using the Rel homology domain (RHD) of the p65 subunit (RelA) of NF-κB as bait, led to the isolation of PIAS3, previously identified as a specific inhibitor of STAT3. We show that PIAS3 can directly associate with p65 using an in vitro pull-down and in vivo coimmunoprecipitation assays. When overexpressed, PIAS3 inhibits NF-κB-dependent transcription induced by treatment with tumor necrosis factor α (TNF-α) or interleukin-1β or by overexpression of TNF family receptors such as RANK, TNFR1, and CD30 or signal transducers of TNF receptor-associated factors (TRAFs), including TRAF2, TRAF5, and TRAF6. Down-regulation of PIAS3 by RNA interference reverses its effect on TNF-α-mediated NF-κB activation. We found that an N-terminal region of PIAS3 is necessary for both the interaction with p65 and the transcriptional suppression activity. In addition, we found that an LXXLL coregulator signature motif located within the N-terminal region of PIAS3 is the minimal requirement for the interaction with p65. Furthermore, we demonstrate that PIAS3 interferes with p65 binding to the CBP coactivator, thereby resulting in a decreased NF-κB-dependent transcription. Taken together, these data suggest that PIAS3 may function in vivo as a modulator in suppressing the transcriptional activity of p65.
UR - http://www.scopus.com/inward/record.url?scp=2642520591&partnerID=8YFLogxK
U2 - 10.1074/jbc.M313018200
DO - 10.1074/jbc.M313018200
M3 - Article
C2 - 15140884
AN - SCOPUS:2642520591
SN - 0021-9258
VL - 279
SP - 24873
EP - 24880
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 23
ER -